Clinical research on probiotics: The interface between science and regulation

Clinical Infectious Diseases

Volumn 46, Issue SUPPL. 2, 2008, Pages

  Tamayo, Carmen ^a  

^a Flora Inc USA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROBIOTIC AGENT;

CLINICAL RESEARCH; CONFERENCE PAPER; DRUG DESIGN; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; EVIDENCE BASED MEDICINE; GOVERNMENT REGULATION; HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ANIMALS; CLINICAL TRIALS AS TOPIC; CONSUMER PRODUCT SAFETY; FOOD LABELING; GOVERNMENT REGULATION; HUMANS; LEGISLATION, FOOD; PROBIOTICS;

EID: 40049089448     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/523332     Document Type: Conference Paper

References (43)

1. Havenar R, Huis in't Veld JHJ. Probiotics: a general view. In: Wood BJB, ed. Lactic acid bacteria in health and disease. Vol 1. Amsterdam: Elsevier Applied Science Publishers, 1992.
2. Joint FAO/WHO Working Group. Guidelines for the evaluation of probiotics in food: report of a Joint FAO/WHO Working Group on Drafting Guidelines for the Evaluation of Probiotics in Food, London, Ontario, Canada. 2002. Available at: http://www.who.int/foodsafety/publications/fs_management/ probiotics2/en/index.html.
3. Floch MH, Hong-Curtiss J. Probiotics and functional foods in gastrointestinal disorders. Curr Treat Options Gastroenterol 2002; 5:311-21.
4. Kim S. Efficacy of probiotics and nutrients in functional gastrointestinal disorders: a preliminary clinical trial. Dig Dis Sci 2006; 51:2134-44.
5. Walker WA, Goulet O, Morelli L, Antoine JM. Progress in the science of probiotics: from cellular microbiology and applied immunology to clinical nutrition. Eur J Nutr 2006; 45(Suppl 1):1-18.
6. Isolauri E. Probiotics in human disease. Am J Clin Nutr 2001; 73:1142S-6S.
7. Leahy SC, Higgins DG, Fitzgerald GF, van Sinderen D. Getting better with bifidobacteria. J Appl Microbiol 2005; 98:1303-15.
8. Rolfe RD. The role of probiotic cultures in the control of gastrointestinal health. J Nutr 2000; 130:396S-402S.
9. Shanahan F. Physiological basis for novel drug therapies used to treat the inflammatory bowel diseases. I. Pathophysiological basis and prospects for probiotic therapy in inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol 2005; 288:G417-21.
10. Walker WA. Mechanisms of action of probiotics. Clin Infect Dis 2008; 46(Suppl 2):S87-91 (in this supplement).
11. Gaskins HR, Croix JA, Nakamura N, Nava GM. Impact of the intestinal microbiota on the development of mucosal defense. Clin Infect Dis 2008; 46(Suppl 2):S80-6 (in this supplement).
12. Goldin BR, Gorbach SL. Clinical indications for probiotics: an overview. Clin Infect Dis 2008; 46(Suppl 2):S96-100 (in this supplement).
13. Saggioro A. Probiotics in the treatment of irritable bowel syndrome. J Clin Gastroenterol 2004; 38:S104-6.
14. McFarland LV. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol 2006; 101:812-22.
15. Sullivan A, Nord CE. Probiotics and gastrointestinal disease. J Intern Med 2005; 257:78-92.
16. Johnston BC, Supina AL, Vohra S. Probiotics for pediatric antibiotic-associated diarrhea: a meta-analysis of randomized placebo-controlled trials. CMAJ 2006; 175:377-83.
17. NASPGHAN Nutrition Report Committee, Michail S, Sylvester F, Fuchs G, Issenman R. Clinical efficacy of probiotics: review of the evidence with focus on children. J Pediatr Gastroenterol Nutr 2006; 43:550-7.
18. Goldin BR. Health benefits of probiotics. Br J Nutr 1998; 80:S203-7.
19. Sanders ME. Probiotics: definition, sources, selection, and uses. Clin Infect Dis 2008; 46(Suppl 2):S58-61 (in this supplement).
20. Senok AC, Ishmaeel AY, Botta GA. Probiotics: facts and myths. Clin Microbiol Infect 2005; 11:958-66.
21. de Roos NM, Katan MB. Effects of probiotic bacteria on diarrhea, lipid metabolism, and carcinogenesis: a review of papers published between 1988 and 1998. Am J Clin Nutr 2000; 71:405-11.
22. Mimura T, Rizello F, Helwig U, et al. Once daily high dose probiotic therapy (VSL 3) for maintaining remission in recurrent or refractory pouchitis. Gut 2004; 53:108-14.
23. Reid G, Kim SU, Kohler GA. Selecting, testing and understanding probiotic microorganisms. FEMS Immunol Med Microbiol 2006; 46:149-57.
24. Hoffman FA. Business considerations in the development of probiotics. Clin Infect Dis 2008; 46(Suppl 2):S141-3 (in this supplement).
25. Hoffman FA, Heimbach JT, Sanders ME, Hibberd PL. Executive summary: scientific and regulatory challenges of development of probiotics as foods and drugs. Clin Infect Dis 2008; 46(Suppl 2):S53-7 (in this supplement).
26. Stanton C, Gardiner G, Meehan H, et al. Market potential for probiotics. Am J Clin Nutr 2001; 73(Suppl):476S-83S.
27. Gibson GR, Fuller R. Aspects of in vitro and in vivo research approaches directed toward identifying probiotics and prebiotics for human use. J Nutr 2000; 130(Suppl 2):391S-5S.
28. Tannock GW. Probiotics: time for a dose of realism. Curr Issues Intest Microbiol 2003; 4:33-42.
29. Saldanha LG. US Food and Drug Administration regulations governing label claims for food products, including probiotics. Clin Infect Dis 2008; 46(Suppl 2):S119-21 (in this supplement).
30. Heimbach JT. Health-benefit claims for probiotic products. Clin Infect Dis 2008; 46(Suppl 2):S122-4 (in this supplement).
31. Degnan FH. The US Food and Drug Administration and probiotics: regulatory categorization. Clin Infect Dis 2008; 46(Suppl 2):S133-6 (in this supplement).
32. Roberfroid MB. Prebiotics and probiotics: are they functional foods? Am J Clin Nutr 2000; 71(Suppl):1682S-7S.
33. Roberfroid MB. Concepts and strategy of functional food science: the European perspective. Am J Clin Nutr 2000; 71(Suppl):1660S-4S.
34. Muth MK, Anderson DW, Domanico JL, Smith JB, Wendling B. Center for Economics Research Triangle Institute economic characterization of the dietary supplement industry. Research Triangle Park, North Carolina: Research Triangle Institute, 1999.
35. Center for Food Safety and Applied Nutrition, Office of Nutritional Products, Labeling, and Dietary Supplements. Claims that can be made for conventional foods and dietary supplements. Revised September 2003. Available at: http://www.cfsan.fda.gov/~dms/hclaims.html. Accessed 27 December 2007.
36. Przyrembel H. Consideration of possible legislation within existing regulatory frameworks. Am J Clin Nutr 2001; 73(Suppl):471S-5S.
37. Santosa S, Farnworth E, Jones PJ. Probiotics and their potential health claims. Nutr Rev 2006; 64:265-74.
38. Ezendam J, van Loveren H. Probiotics: immunomodulation and evaluation of safety and efficacy. Nutr Rev 2006; 64:1-14.
39. von Wright A. Regulating safety of probiotics - the European approach. Curr Pharm Des 2005; 11:17-23.
40. Geier MS, Butler RN, Howarth GS. Inflammatory bowel disease: current insights into pathogenesis and new therapeutic options: probiotics, prebiotics and synbiotics. Int J Food Microbiol 2007; 115:1-11.
41. Fang H, Elina T, Heikki A, Seppo S. Modulation of humoral immune response through probiotic intake. FEMS Immunol Med Microbiol 2000; 29:47-52.
42. Boyle RJ, Robins-Browne RM, Tang ML. Probiotics in clinical practice: what are the risks? Am J Clin Nutr 2006; 83:1256-64.
43. Tannock. New perceptions of the gut microbiota: implications for future research. Gastroenterol Clin North Am 2005; 34:361-82.